companydata.dkcompanydata.dk

VELOXIS PHARMACEUTICALS A/S: Financial statements 2025

CVR: 26527767

Source: annual report 2025, Danish Business Authority

01/04/2024 – 31/03/2025

VELOXIS PHARMACEUTICALS A/S (CVR 26527767) has filed annual accounts for 2025. Equity in the 2025 report amounted to USD 88,648,000. The solvency ratio was 98.6%. The company had 1 employee in the financial year.

Equity
USD 88,648,000
Total Assets
USD 89,916,000
Employees
1

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2025---88.6M USD1
2024----10.5M USD1
2023---2.8M USD1
20220 USD0 USD2.1M USD2.9M USD-
202145.3M USD45.3M USD1.1B USD1.3B USD-

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is VELOXIS PHARMACEUTICALS A/S?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2025

Kenro Yuzaki joins the board of VELOXIS PHARMACEUTICALS A/SSep 4, 2025

As of September 4, 2025, Kenro Yuzaki has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.

Yusuke Hiramatsu leaves the board of VELOXIS PHARMACEUTICALS A/SSep 4, 2025

As of September 4, 2025, Yusuke Hiramatsu has left the board of directors of VELOXIS PHARMACEUTICALS A/S.

About VELOXIS PHARMACEUTICALS A/S

VELOXIS PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Nordhavn, founded in 2002. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named LIFECYCLE PHARMA A/S and PHAROTECH A/S. The management consists of Daisuke Matsuo. The board consists of Keigo Nakatsukasa (chair), Daisuke Matsuo and Kenro Yuzaki. The company is owned by Asahi Kasei Corporation. The company has 1 employee (2022). In 2026, the company reported a net result of DKK -1,553,000. Equity in the 2026 report amounted to DKK 611,587,000.

Source: annual report 2026, Danish Business Authority